## tardive dyskinesia 360

Addressing Persistent Myths & Misconceptions in Tardive Dyskinesia

This activity has been supported through independent educational grants from Neurocrine Biosciences, Inc. and Teva Pharmaceuticals.



#### Craig Chepke, MD, FAPA

Medical Director

Excel Psychiatric Associates

Huntersville, North Carolina

#### Kevin Williams, MS, MPAS, PA-C

CEO and Lead Clinician, OnPoint Behavioral Health

Bethany Yeiser, BS President, CureSZ Foundation

**David Yeiser** Father and Care Partner of Bethany Yeiser

### **Faculty Disclosure**

- Dr. Craig Chepke: Advisory Board—Abbvie, Acadia, Alkermes, Corium, Eisai, Idorsia, Intracellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, Neurocrine, Noven, Otsuka, Takeda, Teva; Advisory Board (Spouse)—Otsuka; Consultant—AbbVie, Alkermes, Corium, Eisai, Intracellular, Janssen, Jazz, Karuna, Lundbeck, Neurocrine, Noven, Otsuka, Takeda, Teva; Grant Research/Support—Acadia, Axsome, Biohaven, Harmony, Neurocrine, Teva; Speaker's Bureau—AbbVie, Acadia, Alkermes, Eisai, Intracellular, Ironshore, Janssen, Jazz, Lundbeck, Merck, Neurocrine, Noven, Otsuka, Sunovion, Takeda, Teva.
- Mr. Kevin Williams: Speakers Bureau—Myriad, Neurocrine Biosciences, Inc., Teva Pharmaceuticals.
- **Bethany Yeiser:** Advisory Board—Alkermes; Grant/Research Support—Cadent Therapeutics, Janssen, Karuna Therapeutics, Neurocrine Biosciences; Speaker—Alkermes, Neurocrine Biosciences.
- David Yeiser: No disclosures

#### Disclosure

- The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational use(s) of drugs, products, and/or devices (any use not approved by the US Food and Drug Administration)
- Applicable CME staff have no relationships to disclose relating to the subject matter of this activity
- This activity has been independently reviewed for balance

CME = continuing medical education.

### **Learning Objectives**

- Discuss with patients the quality of life impact that even low AIMS scores may have in addition to stigma associated with TD
- Describe the clinical risk factors for the development of TD, the prevalence of TD in patients currently taking antipsychotic medication, and the impact on patient quality of life
- Utilize MOA, key clinical trial data and current guideline recommendations to appropriately implement and/or adjust therapy for TD symptom management without specialist referral
- Describe why anticholinergics are not recommended for TD treatment
- Implement strategies to ensure appropriate novel VMAT-2 dosage for each individual patient

#### Myth: TD Is Not a Problem for Most Patients

#### TD Is a Common Presence and It Lurks in Every Practice With Psychiatric Patients



PHP = partial hospitalization program. Uludag K, et al. *Asian J Psychiatr.* 2021;66:102877.


- We clinicians see TD patients in multiple clinical settings
  - Outpatient practices
  - Inpatient practices
  - PHP
  - State hospital setting
  - Long Term Care setting
  - o Multiple others
- TD is frequent. A recent study found it in 36% of patients with chronic schizophrenia
- It is also commonly found in patients with mood disorders

### There are ~ 600,000 People Living with TD in the United States

Prevalence of TD (from 4 adult studies, n=2008)

Cities with Approx. 600,000 People in Them: Milwaukee, Tucson, Baltimore





Correll CU, et al. *J Clin Psychiatry.* 2017;78(8):1136-1147.



## **Definition of Tardive Dyskinesia**

### **Definition of Tardive Dyskinesia**

A type of dyskinesia that typically emerges after long-term use of antipsychotic drugs (DRBAs)

Dyskinesia

**Distortion or impairment of voluntary movement** 

Tardive


#### Appearing or tending to appear late

#### **DSM** Dx (highlights)


- Involuntary movements of the tongue, jaw, trunk, or extremities have developed in association with the use of neuroleptic medication
- The involuntary movements are present over a period of at least 4 weeks and occur in any of the following patterns: 1) choreiform movements (ie, rapid, jerky, nonrepetitive); 2) athetoid movements (ie, slow, sinuous, continual); 3) rhythmic movements (ie, stereotypes)
- Symptoms develop during exposure to a neuroleptic medication or within 4 weeks of withdrawal from an oral neuroleptic medication or within 8 weeks of withdrawal from a depot
- There has been exposure to neuroleptic medication for at least 3 months (1 month, if age  $\geq$  60 years)

DRBA = dopamine receptor blocking agent; DSM = Diagnostic and Statistical Manual of Mental Disorders; Dx = diagnosis. Lerner PP, et al. *Psychiatry Clin Neurosci.* 2015;69(6):321-334.

#### Significant Weakness of These Criteria Are...




### Health Care Utilization Costs Are Elevated in Patients With TD




Note: Percentage of patients with any ER visit pre-index vs post-index. Mean ER visits for individual patients, pre-index vs post-index.

<sup>a</sup>P<0.001 compared with non-TD patients; <sup>b</sup>P<0.01.</li>
ER = emergency room; IP = inpatient; OP = outpatient.
Carroll B, et al. J Manag Care Spec Pharm. 2019;25(7):810-816.



Note: Mean total healthcare costs subdivided into costs for OP pharmacy; OP and IP admissions per patient of matched TD vs matched non-TD cohorts. Any discrepancy in the total mean healthcare costs is due to rounding.

#### TD Is a Highly Impairing Disorder Impacting Physical, Psychological, and Social Domains



- TD imposes substantial burden on the patient's well-being and their psychosocial function, along with their physical functioning
- TD also impacts how patients manage the underlying condition, suggesting that better TD symptom control may reduce patient burden by reducing antipsychotic treatment disruptions and nonadherence
- These results reinforce the need for healthcare providers to assess impact to patients when assessing TD movements

Jain R, et al. Poster presented at: Psych Congress; October 29-November 1, 2021; San Antonio, Texas.

#### Caregivers Are Often the Other Victims of TD

#### Somewhat of Quite a Bit of Very Much of a Burden a Burden a Burden In the previous 7 days, because of their TD I felt... ...with bathing or showering 22.8 21.5 17.7 11.4 ...attend appointments 41.2 22.7 18.6 7.2 ...communicate with others because of speech difficulties caused by TD 37.7 18.8 4.3 ...with massaging body parts that are cramping or moving 22.9 16.9 2.4 ...with driving a car 21.2 8.0 9.7 ...Stressed or strained ...with dressing and grooming 33.3 16.7 2.2 ...irritable, frustrated, or angry 26.4 15.7 6.6 ...annoved or exasperated ...with preparing meals ...with tying shoelaces or putting on shoes 24.7 12.3 6.2 27.8 3.3 ...manage finances or other documents 11.1 ...with gripping or opening things 19.6 10.9 4.3 Respondents (%) 12.9 4.3 ...manage medications 19.8 4.0 ...with shopping for groceries 49.2 26.6 10.5 9.7 ...with household chores 28.7 20.9 4.3 ٠ 12.7 6.3 1.6 ...with making or taking phone calls 25.4

60

40

80

100

#### Figure 1. Burden of Caregiving Tasks

A Little Bit of

a Burden

Not at all

a Burden

Helping them...


Jain R, et al. Poster presented at: Psych Congress; October 29-November 1, 2021: San Antonio, Texas.

Respondents (%)

20

#### Figure 2. Impact on Caregiver Psychological Well-Being

Rarely Sometimes Often Always Never



- The surveyed caregivers (N=162) represented the diversity
- of races/ethnicities present in United States
- Caregivers experienced 46.4% activity impairment because of caring for the patient
- Caregivers who were employed missed 13.8% of work time ٠ (i.e., absenteeism) and experienced 44.0% impairment while working (i.e., presenteeism)

#### An Additional Consequence of Having TD -A Major, Negative Impact on Medication Adherence

#### 48.4%

Skipped doses of an antipsychotic medication or took less than the doctor instructed<sup>a</sup>

#### 39.3%

Stopped taking antipsychotic medication altogether<sup>a</sup>

35.7%

Stopped going to the doctor treating their underlying condition 20.8%

Advised someone else not to take an antipsychotic medication 21.9% None of the above

Jain R, et al. Poster presented at: Psych Congress; October 29-November 1, 2021; San Antonio, Texas.

#### **Deep Learning Point for All of Us**

If optimum outcomes are desired, then it is important to control **TD symptoms** AND focus on **functional impairment** in patients with TD.



## **Meet Bethany**

#### Myth: AIMS is Too Difficult and Takes Too Much Time

- Observer-rated 12-item anchored scale that takes only 5-10 minutes
- Adopted by many agencies for routine clinical use – baseline and periodically
- With FGAs, examine for TD at least every 6 months
- With SGAs and no concomitant FGAs, examine for TD annually
- With patients at high risk for EPS (e.g., older age, history of dystonic reactions, akathisia, clinically significant parkinsonism), examine every 3 months with FGAs or 6 months with SGAs
- Is the *primary outcome measure* in research of drugs for TD

FACIAL				CIRC	CLE	ON	E
AND		<ol> <li>Muscles of Facial Expression         <ul> <li>e.g., Movements of forehead, eyebrows, peri-orbital area, cheeks, include frowning, blinking, smiling, grimacing</li> </ul> </li> </ol>					
ORAL	2. Lips and Peri-oral Area	9	0	1	2	3	4
MOVEMENTS	e.g., puckering, pouting, smacking 3. Jaws	ing lateral movement	0	1	2	3	4
	e.g., biting, clenching, chewing, mouth opening, lateral movement 4. <b>Tongue</b> Rate only increase in movement both in and out of mouth, <b>NOT</b> inability to sustain movement						
EXTREMITY	5. Upper (arms, wrists, hands, fingers) Include choreic movements (i.e., rapid objectively, purposeless, irregular spontaneous), athetoid movements (i.e., slow, irregular, complex, serpentine) Do NOT include tremor (i.e., repetitive, regular, rhythmic)						4
MOVEMENTS	<ol> <li>Lower (legs, knees, ankles, toes)         <ul> <li>e.g., lateral knee movement, foot tapping, he squirming, inversion and eversion of foot</li> </ul> </li> </ol>	eel dropping, foot	0	1	2	3	4
TRUNK MOVEMENTS	<ol> <li>Back, shoulders, hips e.g., rocking, twisting, squirming, pelvic gyrations</li> </ol>					3	4
	8. Severity of abnormal movements None, Norr Minimal						
GLOBAL JUDGMENTS	9. Incapacitation due to abnormal Minimal movements				Sev	/ere 1	
		ess0 Awar d distress2 Awar					
DENTAL	11. Current problems with teeth and/or dentures	No0	⁄es		1		
STATUS	12. Does patient usually wear dentures?	No0	⁄es		1		

### Yes, AIMS Takes Time, But... Three More Reasons To Do This



Some payers require it for VMAT2 inhibitor coverage

		DATE	- DATE			DATE
		4/26/17	DATE <u>5/30/17</u> 0(1)2 3 4	6/14/17	7/31/17	8/8/11
1.	Muscles of Facial Expression e.g. movements of forehead, eyebrows, periorbital area, cheeks, including frowning, blinking, smiling, grimacing				C	
2.	Lips and Perioral Area e.g. puckering, pouting, smacking		0 () 2 3 4			0 1 2 3 4
3.	Jaw Biting, clenching, chewing, mouth opening , lateral movement		0 1 2 3 4			
4.	<b>Tongue</b> Rate only increases in movement both in and out of mouth. NOT inability to sustain movement. Darting in and out of mouth	0 (1) 2 3 4	0 1) 2 3 4	01234	0(1)2 3 4	
5.	Upper (arms, wrists, hands, fingers) Include choreic movements (i.e. rapid objectively purposeless, irregular, spontaneous) athetoid movements. DO NOT INCLUDE TREMOR (i.e. repetitive, regular, rhythmic)		@1234			Q 1 2 3 4
6.	Lower (legs, knees, ankles, toes) Lateral knee movement, foot tapping, heel dropping, foot squirming, inversion and eversion of foot	0 1 2 3 4	0 (1) 2 3 4	0() 2 3 4	0 1 2(3)4	0(1)2 3 4
7.	Neck, shoulders and hips Rocking, twisting, squirming, pelvic gyrations	0 1 2 (3) 4	01234	(0) 1 2 <u>3 4</u>	0 1 (2) 3 4	01234

Enables measurement-based care



#### Helps us slow down and use a systematic thought process

VMAT = vesicular monoamine transporter.

McEvoy JP. J Clin Psychiatry. 2020;81(6):NU19047BR4C. Munetz MR, et al. Hosp Community Psychiatry. 1988;39(11):1172-1177.

- Observer-rated 12-item anchored scale that takes
   5-10 minutes
- Adopted by many agencies for routine clinical use baseline and periodically

#### Items 1 to 7:

4 items dedicated to the face, lips, jaws, tongue.

Only 1 item each for the upper extremities, lower extremities, and trunk.

The sum of the score of these 7 items is the dyskinesia score and is used as the *primary outcome measure* for TD studies

FACIAL				CIRC	CLE	ON	
AND	<ol> <li>Muscles of Facial Expression         e.g., Movements of forehead, eye include frowning, blinking, smiling     </li> </ol>	ebrows, peri-orbital area, cheeks, g. grimacing	0	1	2	3	4
ORAL	2. Lips and Peri-oral Area e.g., puckering, pouting, smackin	<u> </u>	0	1	2	3	4
MOVEMENTS	AOVEMENTS 3. Jaws e.g., biting, clenching, chewing, mouth opening, lateral movement						4
	4. Tongue Rate only increase in movement inability to sustain movement	0	1	2	3	4	
EXTREMITY	<ol> <li>Upper (arms, wrists, hands, fingers) Include choreic movements (i.e., irregular spontaneous), athetoid (i.e., slow, irregular, complex, ser Do NOT include tremor (i.e., re</li> </ol>	0	1	2	3	4	
MOVEMENTS	<ol> <li>Lower (legs, knees, ankles, toes)         <ul> <li>e.g., lateral knee movement, foot tapping, heel dropping, foot squirming, inversion and eversion of foot</li> </ul> </li> </ol>				2	3	4
TRUNK MOVEMENTS	7. Back, shoulders, hips					2	4
	8. Severity of abnormal movements	None, Normal0 Mild Minimal1 Moderate			Sev 	vere 1	
GLOBAL	9. Incapacitation due to abnormal Minimal						
	10. Patient's awareness of abnormal movements RATE ONLY PATIENT'S REPORT	are, No are, Se					
DENTAL	11. Current problems with teeth and/or de	entures No0	Yes		1		
STATUS	12. Does patient usually wear dentures?	No0	Yes		1		

			FACIAL		CIRC	LE O	NE
•	Observer 5-10 min			s of Facial Expression g., Movements of forehead, eyebrows, peri-orbital area, cheeks, clude frowning, blinking, smiling, grimacing	) 1	2	3 4
•		0 = no movements		nd Peri-oral Area g., puckering, pouting, smacking 0	) 1	2	3 4
	baseline	1 = minimal or extreme normal		at of mouth, <b>NOT</b>			3 4 3 4
•		<pre>2 = mild 3 = moderate (and usually quite obvide)</pre>	ous)	ents (i.e., rapid objectively, purposeless, recus), athetoid movements regular, complex, serpentine)			
•	TD annua With pat	4 = severe		NOT include tremor (i.e., repetitive, regular, rhythmic)         0           (legs, knees, ankles, toes)         0           g., lateral knee movement, foot tapping, heel dropping, foot guirming, inversion and eversion of foot         0			3 4 3 4
	-	Sum can equal 7 but would be irreleve	ant if al	shoulders, hips g., rocking, twisting, squirming, pelvic gyrations	1	2	3
	significar	items scored as a "1"		y of abnormal movements None, Normal0 Mild Minimal1 Moderate		Sever	е
	with FGA			citation due to abnormal Minimal 1 Moderate		Sever	e
•	-	Sum of 7 when one item is a "4" and item is a "3" would indicate a severe		t's awareness of abnormal ments CATE ONLY PATIENT'S REPORT			

- Observer-rated 12-item anchored scale that takes 5-10 minutes
- Adopted by many agencies for routine clinical use – baseline and periodically
- With FGAs, examine for TD at least every 6 months
- With SGAs and no concomitant FGAs, examine for TD annually
- With nationts at high risk for FPS (a g

## Global severity: based on the highest single score in the first 7 items

with FGAs or 6 months with SGAs

Is the *primary outcome measure* in research of drugs for TD

• FACIAL			C	CIRC	CLE	ON	E	
AND	<ol> <li>Muscles of Facial Expression         <ul> <li>e.g., Movements of forehead, eyebrows, peri-orbital area, che</li> <li>include frowning, blinking, smiling, grimacing</li> </ul> </li> </ol>	eeks,	0	1	2	3	4	
ORAL	2. Lips and Peri-oral Area     e.g., puckering, pouting, smacking		0	1	2	3		
MOVEMENTS	<ol> <li>Jaws         <ul> <li>e.g., biting, clenching, chewing, mouth opening, lateral movel</li> </ul> </li> </ol>	ment	0	1	2	3	4	
•	<ul> <li>4. Tongue         Rate only increase in movement both in and out of mouth, NG inability to sustain movement     </li> </ul>		0	1	2	3	4	
• EXTREMITY	<ol> <li>Upper (arms, wrists, hands, fingers)         Include choreic movements (i.e., rapid objectively, purposele irregular spontaneous), athetoid movements (i.e., slow, irregular, complex, serpentine)         Do NOT include tremor (i.e., repetitive, regular, rhythmic)     </li> </ol>		0	1	2	3	4	
MOVEMENTS	<ol> <li>Lower (legs, knees, ankles, toes)         <ul> <li>e.g., lateral knee movement, foot tapping, heel dropping, foot squirming, inversion and eversion of foot</li> </ul> </li> </ol>	ſ	0	1	2	3	4	
TRUNK MOVEMENTS	<ol> <li>Back, shoulders, hips e.g., rocking, twisting, squirming, pelvic gyrations</li> </ol>		0		2	0		
	,,	l derate			Severe			
GLOBAL	None, Normal0 Mild	1	0		0.01	/ere		
• JUDGMENTS		derate			4			
	10. Patient's awareness of abnormal movements RATE ONLY PATIENT'S REPORT No Awareness0 Aware, Mild distress2							
DENTAL	11. Current problems with teeth and/or dentures No0	Y	es		1			
STATUS	12. Does patient usually wear dentures? No0	Y	es		1			

Degree of incapacitation due to abnormal movements - the patient will need to be asked to what extent any movements interfere with activities such as eating, drinking, speaking, breathing, dressing oneself, writing, working, leisure activities, being with others, etc.

with FGAs or 6 months with SGAs

Is the *primary outcome measure* in research of drugs for TD

FACIAL			CIRC	CLE	E ONE		
AND	<ol> <li>Muscles of Facial Expression         <ul> <li>e.g., Movements of forehead, eyebrows, peri-orbital area, cheeks, include frowning, blinking, smiling, grimacing</li> </ul> </li> </ol>	0	1	2	3	4	
ORAL	<ol> <li>Lips and Peri-oral Area         <ul> <li>e.g., puckering, pouting, smacking</li> </ul> </li> </ol>	0	1	2	3	4	
<b>10VEMENTS</b>	<ol> <li>Jaws         <ul> <li>e.g., biting, clenching, chewing, mouth opening, lateral movement</li> </ul> </li> </ol>	0	1	2	3	4	
<ul> <li>4. Tongue         <ul> <li>Rate only increase in movement both in and out of mouth, NOT inability to sustain movement</li> </ul> </li> </ul>					3	4	
XTREMITY	<ol> <li>Upper (arms, wrists, hands, fingers)         Include choreic movements (i.e., rapid objectively, purposeless, irregular spontaneous), athetoid movements (i.e., slow, irregular, complex, serpentine)         Do NOT include tremor (i.e., repetitive, regular, rhythmic)     </li> </ol>	0	1	2	3	4	
MENTS	<ol> <li>Lower (legs, knees, ankles, toes)         <ul> <li>e.g., lateral knee movement, foot tapping, heel dropping, foot squirming, inversion and eversion of foot</li> </ul> </li> </ol>	0	1	2	3	4	
10 TS	<ol> <li>Back, shoulders, hips         e.g., rocking, twisting, squirming, pelvic gyrations</li> </ol>	0	1	2	3	4	
	8. Severity of abnormal movements None, Normal0 Mild Minimal1 Moderate						
GLOBAL JUDGMENTS	9. Incapacitation due to abnormal Minimal			Sev 	vere 4		
	10. Patient's awareness of abnormal movements RATE ONLY PATIENT'S REPORT						
DENTAL	······································						
STATUS	12. Does patient usually wear dentures? No0 Y	'es		1			

#### Abnormal Involuntary Movement Scale (AIMS):

Patient's awareness (and distress level) of the abnormal movements (0–4, with 0 noting no awareness, 1 noting being aware with no distress, and 2–4 noting awareness and distress rating from mild to moderate to severe)

It is not unusual for persons with schizophrenia to have little insight into their dyskinetic movements; however, patients with mood disorders may be better able to articulate their distress

AL				0	CIRCLE ONE				
)	1. Muscles of Facial Expression e.g., Movements of forehead, ey include frowning, blinking, smilin	a, cheeks,	0	1	2	3	4		
L	2. Lips and Peri-oral Area e.g., puckering, pouting, smackir		0	1	2	3	4		
ENTS	3. Jaws e.g., biting, clenching, chewing, r	mouth opening, lateral	movement	0	1	2	3	4	
	4. Tongue Rate only increase in movement inability to sustain movement		0	1	2	3	4		
міту	<ol> <li>Upper (arms, wrists, hands, fingers) Include choreic movements (i.e., irregular spontaneous), athetoid (i.e., slow, irregular, complex, se Do NOT include tremor (i.e., re</li> </ol>	0	1	2	3	4			
ENTS	<ol> <li>Lower (legs, knees, ankles, toes)         <ul> <li>e.g., lateral knee movement, fool squirming, inversion and eversio</li> </ul> </li> </ol>	. Lower (legs, knees, ankles, toes) e.g., lateral knee movement, foot tapping, heel dropping, foot							
IK ENTS	7. Back, shoulders, hips e.g., rocking, twisting, squirming,	pelvic gyrations		0	1	2	3		
	8. Severity of abnormal movements	None, Normal0 Minimal1	Mild Moderate			Sev	vere 4		
	9. Incapacitation due to abnormal	None, Normal0 Minimal1	Mild Moderate			Sev 	vere 4		
	10. Patient's awareness of abnormal movements RATE ONLY PATIENT'S REPORT	No Awareness Aware, Mild distress .							
AL	11. Current problems with teeth and/or do	entures No	0 Y	'es		1			
IS	12. Does patient usually wear dentures?	No	0 Y	′es		1			

- Observer-rated 12-item anchored scale that takes
   5-10 minutes
- Adopted by many agencies for routine clinical use baseline and periodically

The last 2 items of the AIMS are yes/no questions regarding dentition status and the use of dentures. Note that people with TD who wear dentures often have problems with them

with FGAs or 6 months with SGAs

Is the *primary outcome measure* in research drugs for TD

	FACIAL			CIRC	CLE	ON	E	
	AND	<ol> <li>Muscles of Facial Expression         <ul> <li>e.g., Movements of forehead, eyebrows, peri-orbital area, cheeks, include frowning, blinking, smiling, grimacing</li> </ul> </li> </ol>	0	1	2	3	4	
	ORAL	<ol> <li>Lips and Peri-oral Area         <ul> <li>e.g., puckering, pouting, smacking</li> </ul> </li> </ol>	0	1	2	3	4	
	MOVEMENTS	<ol> <li>Jaws         <ul> <li>e.g., biting, clenching, chewing, mouth opening, lateral movement</li> </ul> </li> </ol>	0	1	2	3	4	
	4. Tongue     Rate only increase in movement both in and out of mouth, NOT     inability to sustain movement						4	
	EXTREMITY	5. Upper (arms, wrists, hands, fingers) Include choreic movements (i.e., rapid objectively, purposeless, irregular spontaneous), athetoid movements (i.e., slow, irregular, complex, serpentine) Do NOT include tremor (i.e., repetitive, regular, rhythmic)						
	IOVEMENTS	<ol> <li>Lower (legs, knees, ankles, toes)         <ul> <li>e.g., lateral knee movement, foot tapping, heel dropping, foot squirming, inversion and eversion of foot</li> </ul> </li> </ol>	0	1	2	3	4	
	TRUNK IOVEMENTS	7. Back, shoulders, hips e.g., rocking, twisting, squirming, pelvic gyrations	0	1	2	3	4	
_		8. Severity of abnormal movements None, Normal0 Mild Minimal1 Moderate			Severe			
	GLOBAL JUDGMENTS	9. Incapacitation due to abnormal movements None, Normal0 Mild1 Moderate			Sev 	/ere 4		
		10. Patient's awareness of abnormal movements RATE ONLY PATIENT'S REPORT						
	DENTAL		es					
	STATUS	12. Does patient usually wear dentures? No0	es		1		J	

### **Tips on Scoring**


- Thumb-finger tapping, arm extension and walking are "activation" maneuvers used to elicit abnormal movements in other body areas
  - Score activated movements the same way; do not lower those numbers as was proposed at one time
  - An additional activation maneuver that can be used is a cognitive task such as asking the patient to count backwards from 100 or to recite the months of the year in reverse order
- Score the highest amplitude or frequency in a movement on the 0-4 scale, not the average
- The instructions for the AIMS also include an assessment of upper extremity rigidity by flexing and extending the patient's left and right arms, as well as observation of gait, but these are not rated
  - Nevertheless, findings from these actions may be helpful when determining if the patient has drug-induced parkinsonian side effects

### **TD Differential Diagnosis: Key Points**

- TD movements are distinctly different from the rhythmic (3-6 Hz) tremors commonly seen in medication-induced parkinsonism
- It is imperative to distinguish medication-induced parkinsonism from tardive dyskinesia because the treatments commonly used to manage medication-induced parkinsonism (i.e., anticholinergic medications) may worsen the abnormal motor movements associated with tardive dyskinesia
- Moreover, treatments used to manage tardive dyskinesia (i.e., VMAT2 inhibitors) may worsen the symptoms of medication-induced parkinsonism

American Psychiatric Association. The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision. American Psychiatric Association Publishing, Washington, DC, 2022

- Visit the Exhibit Hall on Sunday from 1:45 PM 3:15 PM and attend the AIMS Exam Workshop!
- Practice administering the AIMS exam and discuss your questions and concerns with expert faculty
- Located in the back of the Exhibit Hall, at the end of the 900 aisle



RE-Kinect = Real-World Evaluation Screening Study and Registry of Dyskinesia in Patients Taking Antipsychotic Agents; CMHC = Community Mental Health Center. Caroff SN, et al. *J Clin Psychopharmacology.* 2020;40(3):259-268.

### **Top Telemedicine AIMS Tips**

#### Assessing the lower body

- They can sit further back from the camera, or a helper can hold the device if present
- Angle camera downwards or place device on coffee table or on floor

#### Asynchronous AIMS is an option

- Teach procedures (and give instruction sheets) so patients can record themselves
- Symptoms are variable and may wax and wane, so patients can catch "bad days"
- Saves time and can overcome low speed connection issues

#### Advantages to remote AIMS

- Can stare directly at their face for 10-15 seconds without awkwardness
- No fear/embarrassment of smell when observing feet without socks and shoes

Boes CJ, et al. *Neurol Clin Pract.* 2021;11(2):e157-e164. Srinivasan R, et al. Tremor Other Hyperkinet Mov (NY). 2020;17(10). Cubo E, et al [www.movementdisorders.org]. Accessed February 5, 2021. https://www.movementdisorders.org/MDS-Files1/Education/Webinars/Webinar\_FINAL2.pdf.



## **AIMS Screening and Diagnosis**

### APA Guideline Recommendations on Anticholinergics in DIMDs

The long-term benefits and harms of anticholinergic medications are less clear, and harms may outweigh benefits

> Drinking high-calorie fluids in response to dry mouth from anticholinergics can contribute to weight gain

> > Akathisia tends not to respond to anticholinergics

THE AMERICAN PSYCHIATRIC ASSOCI PRACTICE GUIDELINE FOR THE Treatment of Patients With Schizonbrenia

THIRD EDITION

DIMD = drug-induced movement disorder. APA=American Psychiatric Association APA *Practice Guideline for the Treatment of Patients with Schizophrenia.* 3<sup>rd</sup> ed. APA; 2021.

# Benztropine PI on its Use in Tardive Dyskinesia



"Benztropine is not recommended for use in patients with tardive dyskinesia."

"Useful also in the control of extrapyramidal disorders (except tardive dyskinesia)"

"Antiparkinsonism agents do not alleviate the symptoms of tardive dyskinesia, and in some instances may aggravate them."

PI = prescribing information

US Food and Drug Administration. Drugs@FDA: FDA Approved Drug Products. www.accessdata.fda.gov/scripts/cder/daf/index.cfm.



## MOA of Anticholinergics and VMAT2 Video

#### Anticholinergics and VMAT-2 Inhibitors: Different MOAs, Different Results

Creative services provided by infograph-ed

## Adverse Events Associated with the Use of Benztropine Reported to the FDA, 2017-2021

Category	Q	Number of Cases	Percentage	
Completed Suicide		267	22.46%	
Toxicity To Various Agents		260	21.87%	
Drug Interaction		123	10.34%	
Drug Ineffective		78	6.56%	
Tremor		74	6.22%	
Condition Aggravated		54	4.54%	
Cardio-Respiratory Arrest		45	3.78%	
Confusional State		44	3.70%	
Acute Kidney Injury		44	3.70%	
Totals		1,189	100.00%	
Case Count by Reaction				
Completed Suicide			267	267
Toxicity To Various Age			260	
Drug Interaction		123		
Drug Ineffective	78	125		
Tremor	74			
Tremor Condition Aggravated	54			
Tremor	54			1
Tremor Condition Aggravated	54	200	300	1

Category	(	C Numbe	r of Cases	Percentage	
Completed Suicide			53	42.06%	
Toxicity To Various Age	ents		23	18.25%	
Cardiac Arrest			14	11.11%	
Suspected Suicide			9	7.14%	
Confusional State			7	5.56%	
Constipation			7	5.56%	
Death			6	4.76%	
Dysuria			6	4.76%	
Abdominal Pain Lower			4	3.17%	
Totals			126	100.00%	
Case Count by Reacti	on				
Case Count by Reacti	on			53	5
	on	23		53	5
Completed Suicide	<b>on</b> 14	23		53	5
Completed Suicide Toxicity To Various Age		23		53	5
Completed Suicide Toxicity To Various Age Cardiac Arrest	14	23		53	ŝ
Completed Suicide Toxicity To Various Age Cardiac Arrest Suspected Suicide	9	23		53	5
Completed Suicide Toxicity To Various Age Cardiac Arrest Suspected Suicide Confusional State	9 7	23		53	5
Completed Suicide Toxicity To Various Age Cardiac Arrest Suspected Suicide Confusional State Constipation Death	14 9 7 7 6				
Completed Suicide Toxicity To Various Age Cardiac Arrest Suspected Suicide Confusional State Constipation	14 9 7 7 6	23 20 Number of Ca	40	60	

FAERS = FDA Adverse Event Reporting System. US Food and Drug Administration. FAERS Public Dashboard. Accessed February 5, 2022.

#### Deprescribing Anticholinergics: Use a Gentle Hand



Study of 34 patients in Japan

Studies in patients with schizophrenia/schizoaffective disorder on long-term anticholinergics

#### Study of 20 patients in Canada



Desmarais, JE, et al. *Therapeutic advances in psychopharmacology* 4.6 (2014): 257-267. Ogino, S, et al. *Progress in Neuro-Psychopharmacology and Biological Psychiatry* 35.1 (2011): 78-83. De Leon, J, et al. *Psychiatric Services* 45.6 (1994): 606-607.

## When to Use Anticholinergics in the Setting of TD

#### Anticholinergics <u>are</u> indicated in treatment of Parkinsonism and dystonia

If TD <u>and</u> Parkinsonism or dystonia are present, anticholinergics could be an appropriate choice

Dyskinetic movements could worsen, but the trade-off may be worthwhile in their quality of life

Patients with this kind of mixed presentation may be good candidates for MDS referral




DIP = drug-induced Parkinsonism. MDS = movement disorders specialist.

American Psychiatric Association. *Practice Guideline for the Treatment of Patients with Schizophrenia.* 3<sup>rd</sup> ed. American Psychiatric Association; 2021. Ward KM, et al. *Neurol Ther.* 2018;7(2):233-248.

Myth: Only Movement Disorder Specialists Can Treat TD

#### You may say I'm a dreamer...



#### When to Consider Consultation with a Movement Disorder Specialist:

Family history of other movement disorders (e.g., Huntington's disease)

Pre-existing movement disorder now coexisting with or complicating TD

Persistent parkinsonism despite antipsychotic discontinuation

Prominent dystonia, which may respond to botulinum toxin

Unresponsive to multiple treatments and may be a Deep Brain Stimulation candidate

Psychiatric clinicians can diagnose and treat ~95% of patients with TD

Caroff, SN, et al. The Journal of Clinical Psychiatry 81.2 (2020): 19042.



# What Do the Guidelines Say About the Treatment of TD?

#### APA Guideline Recommendations for Treatment of TD



APA recommends that patients who have moderate to severe or disabling tardive dyskinesia associated with antipsychotic therapy be treated with a reversible inhibitor of the vesicular monoamine transporter 2 (VMAT2).




Disability is in the eye of the beholder. Severity is defined by the impact of functional or quality of life impairment.

- Treatment with a VMAT2 inhibitor can also be considered for patients with mild TD based on patient preference, associated impairment, or effect on psychosocial functioning
- Deutetrabenazine or valbenazine are preferred over tetrabenazine because of the greater evidence base supporting their use
- Anticholinergics do not improve and may even worsen tardive dyskinesia in addition to producing significant side effects.



### Modified 2018 AAN Guideline Updates for Treatment of TD



Deutetrabenazine and valbenazine are established as effective treatments of TD (Level A) and *must* be recommended as treatment.

The recommendations for DRBA withdrawal and switching from typical to atypical DRBAs remain unchanged at level U (insufficient evidence)


There was no role for anticholinergics (e.g. benztropine) in the algorithm

GPi = globus pallidus interna deep brain stimulation; DRBAs=Dopamine Receptor-Blocking Agents Bhidayasiri R, et al. *J Neurol Sci*. 2018;389:67-75.



## Key Clinical Trial Findings of Novel VMAT2 Inhibitors


## Flexible-dose study of Deutetrabenazine (ARM-TD)



Change in Abnormal Involuntary Movement Scale (AIMS) from baseline to Week 12

AIMS, Abnormal Involuntary Movement Scale; ARM-TD, Aim to Reduce Movements in Tardive Dyskinesia; SEM, standard error of the mean. Fernandez HH, et al. Neurology 2017;88:2003–10.

## Fixed-dose study of Deutetrabenazine (AIM-TD)



AIM-TD, Involuntary Movements in Patients with Tardive Dyskinesia; AIMS, Abnormal Involuntary Movement Scale; LS, least squares. Anderson KE, et al. Lancet Psychiatry 2017;4:595–604.

## Deutetrabenazine Safety and Tolerability in Short-Term Studies

Placebo-Controlled TD Studies: Adverse Reactions Reported in  $\geq 2\%$  of Patients Treated with deutetrabenazine


Adverse Reaction	Deutetrabenazine (n=279)	Placebo (n=131)
Headache	5%	8%
Somnolence	4%	7%
Diarrhea	4%	4%
Nasopharyngitis	4%	2%
Fatigue	4%	5%
Insomnia	4%	1%
Anxiety	4%	5%
Upper respiratory tract infection	3%	4%
Dry mouth	3%	5%
Nausea	2%	7%
Weight increased	2%	3%
Urinary tract infection	2%	2%
Depression/Dysthymic Disorder	2%	1%
Akathisia/Agitation/Restlessness	2%	1%
Arthralgia	2%	1%

Only highlighted AEs occurred at a greater rate in patients taking deutetrabenazine than in patients taking placebo

Discontinuation due to AEs occurred in 4% of patients taking deutetrabenazine vs 3% of patients taking placebo


Anderson KE, et al. *Lancet Psychiatry*. 2017;4(8):595-604. Fernandez HH, et al. *J Neurol Neurosurg Psychiatry*. 2019;90(12):1317-1323.

## Fixed-dose study of Valbenazine in North America (KINECT 3)



\**P*<0.05. \*\**P*<0.01. \*\*\**P*≤0.001. SEM = standard error of the mean; VBZ = valbenazine Hauser RA, et al. *Am J Psychiatry*. 2017;174(5):476-484.

## Phase 3 Fixed-Dose Study of Valbenazine in Japan (J-KINECT)



#### \*P<0.001

DBPC = double-blind placebo controlled; AIMS = Abnormal Involuntary Movement Scale; VBZ = valbenazine Horiguchi, J., et al. Psychiatry Clin. Neurosci. Accepted Author Manuscript. (2022).

## Valbenazine Safety and Tolerability in Short-Term Studies

Adverse Events in 6-Week Valbenazine DBPC Studies in North America Reported at  $\geq$  2% and > Placebo

Adverse Event	Valbenazine (n=262) (%)	Placebo (n=183) (%)
Somnolence	10.9%	4.2%
Anticholinergic effects	5.4%	4.9%
Balance disorders/fall	4.1%	2.2%
Headache	3.4%	2.7%
Akathisia (akathisia, restlessness)	2.7%	0.5%
Vomiting	2.6%	0.6%
Nausea	2.3%	2.1%
Arthralgia	2.3%	0.5%

Discontinuation due to AEs occurred in 3% of patients taking valbenazine vs 2% of patients taking placebo

<sup>a</sup>somnolence, fatigue, sedation

<sup>b</sup>dry mouth, constipation, disturbance in attention, vision blurred, urinary retention

°fall, gait disturbance, dizziness, balance disorder

Treatment-Emergent Adverse Events in J-KINECT DBPC Reported at  $\geq 2\%$  and > Placebo

	Placebo (n=84)	VBZ 40 mg (n=85)	VBZ 80 mg (n=84)
Somnolence	2 (2.4%)	10 (11.8%)	21 (25.0%)
Salivary hypersecretion	1 (1.2%)	3 (3.5%)	9 (10.7%)
Nasopharyngitis	6 (7.1%)	6 (7.1%)	4 (4.8%)
Malaise	0 (0.0%)	5 (5.9%)	4 (4.8%)
Akathisia	1 (1.2%)	4 (4.7%)	5 (6.0%)
Insomnia	1 (1.2%)	2 (2.4%)	5 (6.0%)
Schizophrenia	1 (1.2%)	7 (8.2%)	0 (0.0%)
Tremor	0 (0.0%)	0 (0.0%)	5 (6.0%)

TEAE leading to discontinuation: Placebo: 3.6%, VBZ 40 mg: 7.1%, VBZ 80 mg: 16.7%


US Food and Drug Administration. Drugs@FDA: FDA Approved Drug Products. Accessed 4/19/22. www.accessdata.fda.gov/scripts/cder/daf/index.cfm. Horiguchi, J., et al. Psychiatry Clin. Neurosci. Accepted Author Manuscript. (2022).



### Deutetrabenazine and Valbenazine Long-Term Data


## Long-Term Study of Deutetrabenazine (RIM-TD)





Hauser RA, et al. Long-Term Treatment with Deutetrabenazine is Associated with Continued Improvement in Tardive Dyskinesia: Results from the Completed, 3-Year Open-Label Extension Study. Presented at: 2020 Psych Congress Virtual Experience; September 10–13, 2020.

### Long-Term Valbenazine Data




No new safety signals or concerns emerged in either study

DBPC = Double-blind placebo control

\*\**P*<.01 vs placebo. \*\*\**P*<.001 vs placebo. § *P*<.001 vs baseline. Factor SA, et al. *J Clin Psychiatry*. 2017;78(9):1344-1350. Marder SR, et al. *J Clin Psychopharmacol*. 2019;39(6):620-627.

## Effects of Deutetrabenazine in Older Individuals Through 145 Weeks

Mean ages	AE leading to discontinuation after 145 weeks	Mean changes from baseline in total AIMS at week 145	≥50% AIMS response at week 145
45.6 years (range 21–54) in the younger subgroup	<55 years = 8%	<55 years = -6.7	<55 years = 76%
63.1 years (range 55–81) in the older subgroup	≥55 years = 14%	≥55 years = -6.5	≥55 years = 62%



In a post-hoc analysis of a 145-week open-label study, long-term treatment with deutetrabenazine was *well-tolerated* and associated with *sustained improvements* in AIMS score and *treatment success* in both younger and older adults

AIMS = Abnormal Involuntary Movement Scale Sajatovic, M, et al. The American Journal of Geriatric Psychiatry 30.3 (2022): 360-371.

## Effects of Valbenazine in Older Individuals Through 48 weeks

Mean ages	AE leading to discontinuation after 48 weeks	Mean changes from baseline in total AIMS at week 48	≥50% AIMS response at week 48
46.6 years (range 26-54)	<55 years = 9.6%	40 mg: <55 years = -4.4	40 mg: <55 years = 38%
in the younger subgroup		≥55 years = -6.5	≥55 years = 64%
62.4 years (range 55-84)	≥55 years = 18.9%	80 mg: <55 years = -7.2	80 mg: <55 years = 69%
in the older subgroup		≥55 years = -9.2	≥55 years = 74%

In a post-hoc analysis of a 48-week open-label study, long-term treatment with valbenazine was *well-tolerated* and associated with *sustained improvements* in AIMS score and *treatment success* in both younger and older adults

DBPC = double-blind placebo-controlled; AIMS = Abnormal Involuntary Movement Scale Sajatovic, M, et al. International journal of geriatric psychiatry 35.1 (2020): 69-79.

#### Summary



#### Confident diagnosis, confident treatment

There are far too few movement disorder specialists to diagnose or treat every case of TD


Psychiatry can diagnose and treat 95% of patients with TD VMAT2 inhibitors are well tolerated and efficacious at therapeutic doses

You've Got This!

### Myth: VMAT2 Inhibitors Are "One-Size-Fits-All"

2

#### **Basic Similarities and Differences of VMAT2 Inhibitors**




Both deutetrabenazine and valbenazine are efficacious and well-tolerated in treating TD, whatever the underlying diagnosis

Neither requires the discontinuation or change of antipsychotic therapy

Neither was shown to worsen psychiatric illness or increase suicidality in TD trials

RCT= Randomized Controlled Trial; BID = twice daily; PI = HD = Huntington's disease; TID = three times daily. US Food and Drug Administration. Drugs@FDA: FDA Approved Drug Products. www.accessdata.fda.gov/scripts/cder/daf/index.cfm.


### VMAT2 Receptor Occupancy of Valbenazine and Deutetrabenazine



At therapeutic doses, net occupancy of VMAT2 by the active metabolites of both compounds is comparable

Stahl SM. CNS Spectr. 2018;23(4):239-247.


#### **Differences in Metabolism of Valbenazine vs Tetrabenazine**



Grigoriadis DE, et al. *J Pharmacol Exp Ther*. 2017;361(3):454-461. Skor, et al. Drugs in R&D 17.3 (2017): 449-459.

## **Optimizing Efficacy and Managing Side Effects of VMAT2 Inhibitors for TD**

#### Hypothetical Thresholds for VMAT2 Inhibitor Effects






Customize the TD treatment to the individual needs of your patient!

Stahl SM. CNS Spectr. 2018;23(4):239-247. Chepke, C. CureSZ Foundation Newsletter. 2019;8:3.

## Breaking Down Barriers to Using Novel VMAT2 Inhibitors





Caroff SN. Neuropsychiatr Dis Treat. 2019;15:785-794. Velligan DI, et al. J Clin Psychiatry. 2009;70(Suppl 4):1-46.

